HIV-1 protease inhibitors: A review for clinicians

JAMA

Volumn 277, Issue 2, 1997, Pages 145-153

  Deeks, Steven G ^a,b,d   Smith, Mark ^a   Holodniy, Mark ^c   Kahn, James O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HENRY J KAISER FAMILY FOUNDATION   (United States)

^c STANFORD UNIVERSITY   (United States)

^d California HealthCare Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; ASTEMIZOLE; CISAPRIDE; CYTOCHROME P450; DEXAMETHASONE; DIAZEPAM; ENCAINIDE; FENTANYL CITRATE; FLECAINIDE; FLURAZEPAM; HYDROCODONE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; NELFINAVIR; OXYCODONE; PREDNISONE; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; SAQUINAVIR; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG COST; DRUG DEGRADATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; REVIEW; VOMITING;

EID: 0031024623     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.2.145     Document Type: Review

References (59)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al, for the International AIDS Society-USA. Antiretroviral therapy for HIV. infection in 1996:recommendations of an international panel. JAMA. 1996; 276:146-154.
2. Kohl NE, Emini EA, Scheif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988;85:4686-4690.
3. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990;248:358-361.
4. Navia MA, Fitzgerald PMD, McKeever BM, et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 1989;337:615-620.
5. Wlodawer A, Miller M, Jaskolski M, et al. Conserved folding in retroviral proteinases: crystal structure of a synthetic HIV-1 protease. Science. 1989;245:616-621.
6. Invirase (saquinavir mesylate) package insert. Nutley, NJ: Roche Laboratories; Hoffman-LaRoche Inc.
7. Norbeck D, Kumar G, Marsh K, et al. Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors. In: Programs and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; September 17-20, 1995; San Francisco, Calif. Abstract LB7.
8. Cohen C, Sun E, Cameron W, et al. Ritonavirsaquinavir combination treatment in HIV-infected patients. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; September 15-18,1996; New Orleans, La. Abstract LBTb.
9. Norvir (ritonavir) package insert. Abbott Park, 1ll: Abbott Pharmaceuticals.
10. Crixivan (indinavir sulfate) package insert. West Point, Pa: Merck and Company Inc.
11. Viracept (nelfinavir mesylate, AG1343). Expanded Access Program protocol AG1343-515. Agouron Pharmaceuticals: San Diego, Calif.
12. Collier AC, Coombs RW, Schoenfeld DA, et al, for the AIDS Clinical Trials Group. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017.
13. Cameron W, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract LB6a.
14. Norvir (ritonavir) package insert, revised November 1996. Abbott Park, 1ll: Abbott Pharmaceuticals.
15. Gathe J, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman S. A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine vs stavudine alone. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract MoB413.
16. McQuade TJ, Tomasselli AG, Liu L, et al. A synthetic HIV-I protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science. 1990;247:454-456.
17. Meek TD, Labert DM, Dreyer BB, et al. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature. 1990;343: 90-92.
18. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 1991;16:295-305.
19. Vaca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A. 1994;91:4096-4100.
20. Kempf DJ, Marsh KC, Paul D, et al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemather. 1991;35:2209-2214.
21. Kempf DJ, Marsh KC, Derassen JF, etal. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has a high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995;92: 2484-2488.
22. Danner SA, Carr A, Leonard JM, et al, for the European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333:1528-1533.
23. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract LB7.
24. Schapiro JM, Winters MA, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4+ T cell counts in HIV-infected patients. Ann Intern Med. 1996;124:1039-1050.
25. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC). In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract LB.B.6033.
26. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-I protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-1539.
27. Cameron DW, Heath-Chiozzi M, Kravick S, Mills R, Potthoff A, Henry D, for the Advanced HIV Ritonavir Study Group. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir update. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract MoB411.
28. Nabulsi A, Revicki D, Conway D, Maurath C, Mill R, Leonard J. Quality of life consequences of adding ritonavir to current antiviral therapy for advanced HIV patients. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract LB.B.6046.
29. Heath-Chiozzi M, Leonard J, Henry D, et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract LB6b.
30. 3. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.6019.
31. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.931.
32. Coffin JM. HIV Population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
33. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice: recommendations of an International AIDS Society - USA Expert Panel. Nat Med. 1996;2:625-629.
34. Boucher C, Nijhuis M, Schipper P, et al. Detection of drug sensitive infectious HIV-1 after one year of ritonavir treatment in a patient with persistent undetectable plasma HIV-1 RNA. In: Abstracts of the Fifth International Workshop on HIV Drug Resistance; July 3-6, 1996; Whistler, British Columbia. Abstract 70.
35. Markowitz M, Cao Y, Hurley A, et al. Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract LB.B.6031.
36. Markowitz M, Mo H, Kempf D, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 1995;69:701-706.
37. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis. 1996;173:1379-1387.
38. Markowitz M, Cao Y, Hurley A, et al. Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.933.
39. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
40. Perelson AS, Essunger P, Markowitz M, Ho D. How long should treatment be given if we had an antiretroviral regimen that completely blocks HIV replication. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.390.
41. Salminen MO, Robertson D, Sharp PM, Han BH, Burker DS, McCutchan RE. Continuous in vivo recombination between HIV-1 strains of genetic subtypes A and C. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract TuA511.
42. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
43. Eberle J, Bechowsky B, Rose D, et al. Resistance of HIV type 1 protease inhibitor Ro 31-8959. AIDS Res Hum Retroviruses. 1995;11:671-676.
44. Condra JH, Schleif WA, Blahy OM, et al. In vivo evolution of resistance to the HIV-1 protease inhibitor indinavir. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 145.
45. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270-8276.
46. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV-1 protease confers resistance to ritonvair. Nat Med. 1996;2:760-766.
47. Patick AK, Duran M, Cao Y. Genotypic and phenotypic characterization of HIV-1 variance isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. In: Abstracts of the Fifth International Workshop on HIV Drug Resistance; July 3-6, 1966; Whistler, British Columbia. Abstract 29.
48. Emini E, Condra JH, Schleif WA, et al. Maintenance of long-term virus suppression in patients treated with the HIV-1 protease inhibitor, Crixivan (indinavir). In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract MO.B.170.
49. Korneyeva M, Molla A, Kempf D, et al. Clinical and virological responses to ritonavir, an inhibitor of HIV protease. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract MO.B.1137.
50. Condra JH, Holder DJ, Schleif WA, et al. Bidirectional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.932.
51. Winslow R. Health plans to cover new AIDS drugs, but issues of cost, treatment remain. Wall Street Journal. July 12, 1996:A2.
52. Ho DD. Time to hit HI V: early and hard. N Engl J Med. 1995;333:450-451.
53. Information Marketing System America. National Prescription Audit. Plymouth Meeting, Pa: 1996.
54. People With AIDS (PWA) Health Group. Protease Inhibitors At-A-Glance Fact Sheet. New York, NY: People With AIDS Working for Health Inc; 1996.
55. Kelly JF. Fiscal Status of State AIDS Drug Assistance Programs: Findings from a January 1996 National Survey of State AIDS Directors. Washington, DC: National Alliance of State and Territorial AIDS Directors; 1996.
56. Fornataro K, Jeffery R, Fornataro N. Access Project Report. New York, NY: AIDS Treatment Data Network; 1995.
57. Hammer SM, Katzenstein DA, Hughes MD, et al, for The AIDS Clinical Trials Group Study 175 Study Team. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
58. Montaner J, Cooper D, Katlama C, et al, for the CEASAR coordinating committee. CEASAR, confirmation of the clinical benefit of 3TC (Epivir) in HIV-disease: preliminary results. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans, La. Abstract LB6.
59. Pollard R, Petersen D, Hardy D, et al. Stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot randomized double-blind trial. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract ThB293.